Fig 1.
Patients’ baseline disposition towards antiretrovirals was based on: a) the complexity of the former regimen; b) the frequency of single antivirals in the former regimens of the population; c) the complexity of drug resistance at baseline; d), e), f) the frequency of single baseline mutations in the population by reverse transcriptase, protease and integrase regions, respectively.
ELV/c = elvitegravir/cobicistat, AZT = zidovudine, LPV = lopinavir, /r = boosted with ritonavir, ATV = atazanavir, MVC = maraviroc, NVP = nevirapine, EFV = efavirenz, ETV = etravirine, ABC = abacavir, RPV = rilpivirine, DRV = darunavir, 3TC = lamivudine, FTC = emtricitabine, TDF = tenofovir, RAL = raltegravir.
Fig 2.
Virologic response in the global population (A) and in the subgroup that has reached week 48 (B).
Proportion of viremia ranks over time, and median viral decay (range) and trend in viremic subjects.
Fig 3.
Absolute CD4+ T-cell count (i) and proportion of CD4+ T-cells (ii) in the global population and in the subgroup that reached week 48, median (range).